Karin Andersson is a Gastroenterology physician affiliated with Harvard University. OpenAlex indexes 63 publications with 1,701 citations (h-index 19); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Fruit St
Massachusetts General Hospital Grj 722
Boston, MA 021142621
Telephone
617-724-6113Registry record last updated 23 Oct 2012.
Clinical trials
- Phase I/II Dose Ranging CHRONSEAL® Study in Venous Leg Ulcers
Sponsor: Kringle Pharma Europe AB
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Instylla, Inc.Program year20241 payment
- Instylla, Inc.Program year20231 payment
- INTERCEPT PHARMACEUTICALS, INC.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
58%Osmotic Laxative20%Gavilyte-G100%Part D≥60 patientsProton pump inhibitor19.3%Omeprazole81%Pantoprazole Sodium19%Part D<11 patients+ 2 more classes in this area
Anti-infectives
22%Nucleoside and nucleotide reverse transcriptase inhibitors17.3%Vemlidy100%Part D<11 patientsHepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor4.7%Entecavir100%Part D<11 patientsCancer & immunology
9.3%Purine Antimetabolite5.3%Azathioprine100%Part D<11 patientsCalcineurin inhibitor4%Tacrolimus100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Gender Differences in Colonoscopy: Implications for Clinical Practice and Female Gastroenterologists
Digestive Diseases and Sciences
2021 - Incidence and risks of caesarean section in women aged greater than 40 years
Italian Journal of Gynaecology and Obstetrics
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Mark Shrime, MD
Harvard University
Thoralf Sundt, MD
Harvard University
Dhaval Kolte, MBBS, PhD
Harvard University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”